EUROFINS SCIENT Debt to Equity Ratio 2018-2024 | ERFSF
Current and historical debt to equity ratio values for EUROFINS SCIENT (ERFSF) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. EUROFINS SCIENT debt/equity for the three months ending December 31, 2024 was 0.58.
| EUROFINS SCIENT Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $5.96B | $5.83B | 1.02 |
| 2024-06-30 | $5.92B | $5.70B | 1.04 |
| 2023-06-30 | $5.73B | $5.53B | 1.04 |
| 2022-12-31 | $5.51B | $5.11B | 1.08 |
| 2021-12-31 | $5.51B | $5.53B | 1.00 |
| 2021-06-30 | $5.48B | $4.95B | 1.11 |
| 2020-12-31 | $5.55B | $4.25B | 1.31 |
| 2020-06-30 | $5.08B | $3.83B | 1.33 |
| 2019-12-31 | $5.52B | $3.25B | 1.70 |
| 2019-06-30 | $5.56B | $3.08B | 1.81 |
| 2018-12-31 | $5.30B | $3.22B | 1.65 |
| 2018-06-30 | $4.04B | $3.04B | 1.33 |
| 2017-12-31 | $3.79B | $2.81B | 1.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.529B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $132.070B | 24.77 |
| Elevance Health (ELV) | United States | $84.109B | 10.85 |
| CVS Health (CVS) | United States | $76.951B | 9.56 |
| Cencora (COR) | United States | $56.664B | 19.71 |
| DiDi Global (DIDIY) | China | $22.591B | 34.29 |
| Natera (NTRA) | United States | $20.935B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.251B | 12.97 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Revvity (RVTY) | United States | $10.529B | 18.12 |
| ICON (ICLR) | Ireland | $10.336B | 9.61 |
| Viatris (VTRS) | United States | $9.730B | 3.34 |
| Doximity (DOCS) | United States | $9.525B | 44.37 |
| Avantor (AVTR) | United States | $8.647B | 12.56 |
| HealthEquity (HQY) | United States | $8.564B | 42.13 |
| Medpace Holdings (MEDP) | United States | $8.476B | 22.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.176B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.716B | 13.16 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.048B | 37.47 |
| Bausch + Lomb (BLCO) | Canada | $3.990B | 23.52 |
| Sotera Health (SHC) | United States | $3.452B | 19.61 |
| Surgery Partners (SGRY) | United States | $2.922B | 38.00 |
| Alignment Healthcare (ALHC) | United States | $2.865B | 0.00 |
| Concentras Parent (CON) | United States | $2.710B | 15.66 |
| Organon (OGN) | United States | $2.259B | 2.40 |
| Ardent Health Partners (ARDT) | United States | $2.091B | 8.91 |
| GeneDx Holdings (WGS) | United States | $2.043B | 78.68 |
| Premier (PINC) | United States | $1.899B | 14.41 |
| Progyny (PGNY) | United States | $1.759B | 38.72 |
| PACS (PACS) | United States | $1.497B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.336B | 26.71 |
| Teladoc Health (TDOC) | United States | $1.195B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.165B | 8.86 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.944B | 14.74 |
| Agilon Health (AGL) | United States | $0.919B | 0.00 |
| Nutex Health (NUTX) | United States | $0.890B | 13.45 |
| AMN Healthcare Services Inc (AMN) | United States | $0.795B | 7.44 |
| QDM (QDMI) | Hong Kong, SAR China | $0.743B | 0.00 |
| Embecta (EMBC) | United States | $0.626B | 4.22 |
| InnovAge Holding (INNV) | United States | $0.531B | 0.00 |
| LifeMD (LFMD) | United States | $0.524B | 0.00 |
| Enhabit (EHAB) | United States | $0.518B | 42.58 |
| Auna S.A (AUNA) | Luxembourg | $0.492B | 11.08 |
| SBC Medicals (SBC) | United States | $0.471B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.462B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.405B | 0.00 |
| Oncology Institute (TOI) | United States | $0.228B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.215B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.137B | 22.33 |
| OncoCyte (OCX) | United States | $0.096B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.066B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| Biodesix (BDSX) | United States | $0.050B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.043B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.025B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |